AMBU B Ambu A/S Class B

AMBU UPGRADES FULL-YEAR 2022/23 EARNINGS EXPECTATIONS ON THE BACK OF PRELIMINARY Q3 2022/23 RESULTS

AMBU UPGRADES FULL-YEAR 2022/23 EARNINGS EXPECTATIONS ON THE BACK OF PRELIMINARY Q3 2022/23 RESULTS

Ambu raises its expectations for EBIT margin before special items to 5 - 6% (previously 3 - 5%) for the full-year 2022/23, based on its preliminary Q3 results. For Q3 2022/23, EBIT before special items totalled DKK 91m (DKK 42m), with an EBIT-margin before special items of 7.6% (3.7%), mainly driven by a better-than-expected gross margin, based on product mix and lower distribution costs.



PRELIMINARY FINANCIAL HIGHLIGHTS FOR Q3 2022/23

Last year’s comparative figures are stated in brackets.

  • Revenue was DKK 1,195m (DKK 1,128m), with organic growth of 8% (8%), driven by strong growth in Endoscopy Solutions. Reported growth for the quarter was 6% (16%). Year-to-date, organic growth was 5% (5%), with reported growth of 7% (10%).
  • Gross margin was 56.2% (55.8%) and 56.8% (58.2%) year-to-date. The gross margin is mainly impacted by a strengthened product mix, compared to plan, driven by Endoscopy Solutions.
  • EBIT before special items was DKK 91m (DKK 42m), corresponding to a margin of 7.6% (3.7%). Year-to-date, EBIT before special items ended at DKK 205m (DKK 129m), corresponding to a margin of 5.8% (3.9%), mainly driven by the gross margin and lower distribution costs.



REVISED OUTLOOK FOR THE FISCAL YEAR 2022/23

Based on the Q3 results, Ambu maintains its guidance on organic revenue growth and raises its guidance on EBIT margin before special items as per below:



Outlook FY 2022/23Previously July 10, 2023
Organic revenue growth5 - 8%5 - 8%
EBIT margin before special items3 - 5%5 - 6%





The stated preliminary results for Q3 2022/23 are unaudited. Ambu will release its full Q3 2022/23 interim earnings results, as previously announced, on 31 August 2023.



Ambu A/S

Baltorpbakken 13

2750 Ballerup

Denmark

Tel.

CVR no.: 63 64 49 19



CONTACT

Investors

Nicolai Thomsen

Director, Investor Relations & Strategic Finance



Media

Tine Bjørn Schmidt

Head of Corporate Communications





ABOUT AMBU

Since 1937, Ambu has been rethinking solutions, together with healthcare professionals, to save lives and improve patient care. Today, millions of patients and healthcare professionals worldwide depend on the efficiency, safety and performance of our single-use endoscopy, anaesthesia and patient monitoring solutions. Headquartered near Copenhagen in Denmark, Ambu employs around 4,500 people in Europe, North America, Latin America and Asia Pacific. For more information, please visit Ambu.com.

Attachment



EN
10/07/2023

Underlying

AMBU BAmbu A/S Class B

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ambu A/S Class B

Free Trial
AMBU B Ambu A/S Class ...

Ambu AS: 1 director

A director at Ambu AS bought 12,500 shares at 118.560DKK and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

AMBU B AMBU A/S CLASS B
02/09/24 February 9, 2024 1 EN
 PRESS RELEASE
Free
AMBU B Ambu A/S Class ...

Ambu A/S: Reporting of transactions made by persons discharging manage...

Ambu A/S: Reporting of transactions made by persons discharging managerial responsibilities Pursuant to the Market Abuse Regulation, article 19, Ambu A/S hereby notifies receipt of information of the following transaction(s) made by persons discharging managerial responsibilities in Ambu A/S and/or their closely associated persons related to Ambu A/S’s shares admitted to trading and official listing on Nasdaq Copenhagen A/S.   The attached document discloses the data of the transactions made in Ambu shares.  Attachment

February 9, 2024 1 EN
 PRESS RELEASE
Free
AMBU B Ambu A/S Class ...

GRANT OF PERFORMANCE SHARE UNITS

GRANT OF PERFORMANCE SHARE UNITS Pursuant to Ambu A/S’ (Ambu) Remuneration Policy, a total of 172,956 Performance Share Units (PSUs) related to Ambu’s long-term incentive programme (LTIP) for 2023/24 have been granted on 6 February 2024 with retroactive effect from 1 January 2024. 49,109 of the PSUs have been granted to the Executive Management and 123,847 of the PSUs have been granted to other key employees.  The LTIP covers the financial year 2023/24, and the final allocation of PSUs is conditional upon achievement of two key performance indicators (organic revenue growth and EBIT marg...

February 6, 2024 1 EN
Jesper Ingildsen
  • Jesper Ingildsen
Free Trial
AMBU B Ambu A/S Class ...

Ambu (Buy, TP: DKK130.00) - Strong Q1 suggests promising 2024

With a c20% EBIT beat driven by the top line and profitability, Q1 showed Ambu is off to a strong start to 2023/24. However, the guidance was maintained and remains conservative in our view, while recent price rises to the legacy business and more reimbursement for the aScope 5 leave further upside potential. We reiterate our BUY and have raised our target price to DKK130 (120).

AMBU B AMBU A/S CLASS B
01/31/24 January 31, 2024 1 EN
 PRESS RELEASE
Free
AMBU B Ambu A/S Class ...

INTERIM REPORT FOR Q1 2023/24

INTERIM REPORT FOR Q1 2023/24 In Q1 2023/24, Ambu delivered 14% organic revenue growth and a 10.0% EBIT margin before special items. This was driven by Endoscopy Solutions growing 25%, due to continued high double-digit growth within urology and ENT, combined with pulmonology growing 18%. “I am pleased with the performance within the first quarter of the year, showcasing our continued commitment to delivering strong profitable growth. With 25% growth in Endoscopy Solutions, an increased profitability level and a positive free cash flow of DKK 135m, we are off to a solid start ...

January 30, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch